The global circulating tumor cells market size is estimated to reach USD 38.95 billion by 2033, registering to grow at a CAGR of 13.92% from 2026 to 2033, according to a new report by Grand View Research, Inc. This is attributed to rising prevalence of cancer worldwide, increasing demand for non-invasive cancer diagnostic tools, and advancements in circulating tumor cells (CTC) technologies.
In recent years, CTCs are increasingly used for determining the prognosis of cancer and helping clinicians decide the type of therapy required for cancer treatment. CTCs have wide applications in several areas of cancer management—early detection of cancer, risk assessment of cancer recurrence, guidance for therapies, and continuous monitoring of a patient during cancer treatment. The development of various tumor markers utilizing CTCs, which can be used to diagnose or monitor cancer, is expected to boost the adoption of CTCs over the forecast period. Therefore, it can be concluded that the detection of CTCs in the peripheral blood of patients with cancer acts as a promising diagnostic tool. For instance, quantitation and genomic profiling of CTCs enables cost-effective & accurate noninvasive monitoring of prostate cancer. The detection of CTCs is predictive for survival of cancer patients.
The limited applicability of these cells in rare cancers has hampered revenue growth to a certain extent. Circulating tumor cells are not applicable to tumors characterized by EpCAM negativity or low expression, such as neurogenic cancers. For instance, there is negligible evidence for the characterization of circulating tumor cells for sarcoma. Conversely, numerous methods are being studied for the isolation of these cells, which include methods based on epithelial antigen-targeted antibodies, anticipating to overcome these challenges in the near future.
However, in recent years, there has been a push for practical application, largely as a result of a wave of large players centralizing the technology through acquisitions and numerous partnerships with pharmaceutical firms to advance the formation of a value chain and speed up the CTC market’s growth. For instance, in June 2023, to develop a novel test for the detection of tumor cells that metastatic cancers shed into the blood, the University of Washington School of Medicine collaborated with RareCyte, Inc., which is a biotech company headquartered in Seattle. In addition, according to the research, the understanding of the circulating tumor cells in the bloodstream can track the changes in tumor cells, thus optimizing the treatment.
Request a free sample copy or view report summary: Circulating Tumor Cells Market Report
Based on technology, The CTC detection and enrichment methods segment accounted for the largest revenue share of 50.68% in 2025 owing to the increased availability of products for CTC enrichment and isolation as well as high usage and product penetration across the globe
CTC analysis is expected to register the fastest CAGR during the forecast period due to the growing application potential of CTC analysis for investigational research, drug development, and biomarker studies
Based on application, the research segment dominated the market in 2025 and it is expected to witness the fastest CAGR from 2026 to 2033
Kits & reagent dominated the product segment in 2025, and it is expected to witness the fastest growth in forecast period of 2026-2033
Based on specimen, the blood segment dominated the market in 2025. The other body fluids segment is expected to witness the fastest CAGR from 2026 to 2033
Based on end-use, the research & academic institutes segment dominated the market in 2025 due to increasing focus on research and development activities for cancer diagnosis and treatment
North America dominated the CTC market in 2025, owing to factors such as the presence of key market players Bio-Techne Corporation, Precision Medicine Group LLC, Epic Sciences, APPLIED DNA SCIENCES, INC., and LungLife AI, Inc. and the growth in pharmaceutical & biotechnology research sectors in this region
Asia Pacific is expected to register the fastest CAGR over the forecast period due to several companies expanding their presence in countries like Japan
Grand View Research has segmented the global circulating tumor cells market based on technology, application, product, specimen, end-use, and region.
Circulating Tumor Cells Technology Outlook (Revenue, USD Million, 2021 - 2033)
Circulating Tumor Cells CTC Detection & Enrichment Methods
Immunocapture (Label-based)
Positive Selection
Negative Selection
Size-based Separation (Label-free)
Membrane-based
Microfluidic-based
Density-based Separation (Label-free)
Combined Methods
CTC Direct Detection Methods
CTC Analysis
Circulating Tumor Cells Application Outlook (Revenue, USD Million, 2021 - 2033)
Clinical
Risk Assessment
Screening and Monitoring
Research
Cancer Stem Cell & Tumorogenesis Research
Drug/Therapy Development
Circulating Tumor Cells Product Outlook (Revenue, USD Million, 2021 - 2033)
Kits & Reagents
Blood Collection Tubes
Devices or Systems
Circulating Tumor Cells Specimen Outlook (Revenue, USD Million, 2021 - 2033)
Blood
Bone Marrow
Other Body Fluids
Circulating Tumor Cells End Use Outlook (Revenue, USD Million, 2021 - 2033)
Research and Academic Institutes
Hospital and Clinics
Diagnostic Centers
Circulating Tumor Cells Regional Outlook (Revenue, USD Million, 2021 - 2033)
North America
U.S.
Canada
Mexico
Europe
Germany
UK
France
Italy
Spain
Sweden
Denmark
Norway
Asia Pacific
China
Japan
India
South Korea
Australia
Thailand
Latin America
Brazil
Argentina
Middle East and Africa (MEA)
South Africa
UAE
Saudi Arabia
Kuwait
List of Key Players in Circulating Tumor Cells Market
QIAGEN
Bio-Techne Corporation
Precision Medicine Group, LLC.
Bio-Rad Laboratories, Inc.
Natera, Inc.
Illumina, Inc.
Cell Microsystems
Greiner Bio One International GmbH
Ikonisys Inc.
Miltenyi Biotec
"The quality of research they have done for us has been excellent..."